Related Experiment Videos

Clinical Trials in Older Adults with Cardiovascular Multimorbidity: A Perspective on Pragmatic Trial Design

Clara Bonanad1,2,3, Didier Sánchez-Ospina4, Sergio García-Blas1,2,3

  • 1Cardiology Department, University Clinical Hospital of Valencia, 46010 Valencia, Spain.

Insights

Aging populations face cardiovascular disease challenges. Current trials often exclude frail older adults, necessitating new, geriatric-focused research designs for better real-world applicability.

Area of Science:

  • Geriatric Cardiology
  • Clinical Trial Methodology
  • Cardiovascular Disease Research

Background:

  • Population aging increases cardiovascular disease (CVD) burden in older adults with multimorbidity and frailty.
  • Existing randomized clinical trials (RCTs) often use homogeneous participants, limiting applicability to complex geriatric populations.
  • Geriatric cardiology requires trial designs that better reflect real-world patient complexity.

Purpose of the Study:

  • To conduct a comparative methodological analysis of two European cardiovascular RCTs (HI-COR-65 and SENEKA).
  • To propose a geriatric-oriented framework for improving future cardiovascular trial design in older adults with multimorbidity.
  • To address limitations in current trial designs regarding representativeness, patient complexity, and outcome relevance.

Main Methods:

  • Qualitative comparative analysis of two cardiovascular RCTs across five domains: population representativeness, clinical objectives, exclusion criteria, multidisciplinarity, and patient perspective.
  • Evaluation of how trials operationalize geriatric complexity, stratification, and patient-centered outcomes.
  • Review of intervention models and participation burden.

Main Results:

  • Both analyzed trials made progress by including older adults with cardiovascular multimorbidity.
  • Recurring limitations include inadequate operationalization of geriatric complexity, potential selection of robust participants, misaligned outcome hierarchies, and predominantly pharmacological, monodisciplinary interventions.
  • Current trial designs often fail to fully integrate comprehensive geriatric assessment or patient priorities.

Conclusions:

  • Future cardiovascular trials in older adults need pragmatic, complexity-sensitive designs moving beyond chronological inclusion.
  • The proposed Comprehensive Geriatric Cardiology (COMGERCARDIO) framework integrates geriatric assessment, adaptive interventions, patient-centered outcomes, and stratified analysis.
  • The COMGERCARDIO framework aims to generate scientifically robust, clinically usable, and equitable evidence for aging populations.

Related Concept Videos

Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion

In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...